Voxzogo (vosoritide) for Achondroplasia (conversion to full approval)
The FDA is expected to decide on Voxzogo for Achondroplasia (conversion to full approval) by February 28, 2027, under a sNDA from BioMarin.
What is being decided
BioMarin has a sNDA under FDA review for Voxzogo (vosoritide) in Achondroplasia (conversion to full approval). Application to convert the 2021 accelerated approval into full approval.
Who this decision matters to
Achondroplasia is the most common form of short-limbed dwarfism, caused by a mutation in the FGFR3 gene that disrupts the conversion of cartilage to bone in the growth plates. This results in disproportionate short stature with an average-size trunk but shortened arms and legs. About 80% of cases arise from new spontaneous mutations rather than being inherited from an affected parent.
Prevalence: Approximately 1 in 25,000 live births; estimated 25,000 to 30,000 people in the United States. See our full Achondroplasia page for current treatments, recruiting trials, and community resources.
What each outcome would mean
An approval starts a second race rather than ending the first one: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. Our guide to the 90 days after a rare disease approval explains the timeline and the moves families can make on day 1.
A complete response letter would mean the FDA declined to approve in the application's current form. CRLs are often about manufacturing or data presentation rather than efficacy, and resubmission is common. Either way, this page updates with the outcome and what it means.
Where Achondroplasia treatment stands today
Clinical trials for achondroplasia are exploring multiple strategies to promote bone growth and address the complications of FGFR3 overactivation. Voxzogo (vosoritide) established the path for growth-promoting therapies, and newer approaches including FGFR3 inhibitors, gene therapy, and combination treatments are in development. Trials measure treatment response through growth velocity, body proportions, and functional outcomes like mobility and respiratory function. For children, early enrollment in growth-promoting trials may maximize benefit while growth plates remain open. Adults with achondroplasia may benefit from trials addressing spinal stenosis, sleep apnea, and pain management. Your geneticist, orthopedic specialist, or skeletal dysplasia clinic can help evaluate whether current trials are appropriate. Little People of America and the MAGIC Foundation maintain information on clinical trials and connect families with specialized care centers.
Meanwhile, 12 Achondroplasia trials are recruiting
Whatever the FDA decides here, research on Achondroplasia does not stop. A few currently enrolling studies, US sites first:
Get notified when new achondroplasia trials open or existing trials change status, add sites, or update eligibility.
Frequently asked questions
When will the FDA decide on Voxzogo?
The FDA's target decision date (PDUFA date) for Voxzogo in Achondroplasia (conversion to full approval) is February 28, 2027, disclosed by BioMarin. The agency can act before this date and occasionally runs past it.
What is Voxzogo being reviewed for?
BioMarin submitted a sNDA for Voxzogo in Achondroplasia (conversion to full approval). Application to convert the 2021 accelerated approval into full approval.
What happens after the Voxzogo decision?
If approved, availability is not immediate: specialty pharmacy setup, insurance review, and patient assistance typically take weeks even when everything goes right. If the FDA issues a complete response letter, the application was not approved in its current form; CRLs are often about manufacturing or data presentation rather than efficacy, and sponsors frequently resubmit. This page updates with the outcome either way.
Where this date comes from
The FDA does not publish PDUFA dates; companies disclose them. This one comes from BioMarin press release. Dates can move, and the FDA can act early or late. This page rechecks against our calendar, which is re-verified weekly.